Equities

Haleon PLC

HLN:LSE

Haleon PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)398.10
  • Today's Change-1.20 / -0.30%
  • Shares traded8.15m
  • 1 Year change5.32%
  • Beta0.3806
Data delayed at least 20 minutes, as of Feb 06 2026 16:36 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy4
Outperform9
Hold2
Sell2
Strong Sell0

Share price forecast

The 14 analysts offering 12 month price targets for Haleon PLC have a median target of 435.00, with a high estimate of 517.00 and a low estimate of 335.00. The median estimate represents a 9.27% increase from the last price of 398.10.
High29.9%517.00
Med9.3%435.00
Low-15.9%335.00

Dividends

In 2024, Haleon PLC reported a dividend of 0.07 GBP, which represents a 10.00% increase over last year. The 17 analysts covering the company expect dividends of 0.07 GBP for the upcoming fiscal year, an increase of 4.55%.
Div growth (TTM)10.00%
More ▼

Earnings history & estimates

On Feb 27, 2025, earnings of 4.32 per share. This result exceeded the 3.92 expectation of the one analyst covering the company
The next earnings announcement is expected on Feb 25, 2026.
Average growth rate+11.48%
Haleon PLC reported annual 2024 earnings of 17.90 per share on Feb 27, 2025.
Average growth rate-1.26%
More ▼

Revenue history & estimates

Haleon PLC had 3rd quarter 2025 revenues of 2.80bn. This bettered the 2.75bn consensus of the 3 analysts covering the company. This was 4.11% below the prior year's 3rd quarter results.
Average growth rate+0.32%
Haleon PLC had revenues for the full year 2024 of 11.23bn. This was 0.61% below the prior year's results.
Average growth rate+1.74%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.